Establishment Labs (NASDAQ:ESTA) Price Target Raised to $88.00

Establishment Labs (NASDAQ:ESTA) had its target price increased by BTIG Research from $86.00 to $88.00 in a report published on Tuesday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

Several other analysts have also recently issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho boosted their target price on Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Citigroup boosted their price objective on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Finally, Canaccord Genuity Group upped their price target on shares of Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Establishment Labs Trading Down 1.5%

NASDAQ ESTA opened at $77.15 on Tuesday. The company has a market cap of $2.24 billion, a P/E ratio of -44.34 and a beta of 0.99. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $83.31. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10. The company has a 50-day moving average of $71.21 and a 200-day moving average of $58.00.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. The business had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. During the same period last year, the company earned ($1.19) earnings per share. The company’s quarterly revenue was up 45.2% on a year-over-year basis. As a group, equities analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

Several large investors have recently modified their holdings of ESTA. Quarry LP purchased a new stake in shares of Establishment Labs during the third quarter worth about $34,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs in the 4th quarter valued at approximately $47,000. State of Wyoming acquired a new stake in shares of Establishment Labs during the third quarter worth approximately $71,000. Osaic Holdings Inc. increased its stake in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the last quarter. Finally, CWM LLC raised its holdings in Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after acquiring an additional 686 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Multiple brokerages raised price targets and kept bullish ratings — Canaccord raised its target to $90 and kept a Buy rating, Stephens raised to $90 with an Overweight, Mizuho lifted to $100 with an Outperform, and BTIG moved to $88 with a Buy — reinforcing analyst conviction and upside. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Q4 2025 results beat expectations: revenue (~$64.6M) and EPS beat consensus, with year‑over‑year revenue growth (~45%) — results and commentary underpin the recent analyst upgrades. Q4 2025 Earnings Call Summary (Yahoo)
• Positive Sentiment: Management provided 2026 guidance targeting at least 25% revenue growth and emphasized expansion of minimally invasive platforms — a clear growth thesis that supports higher valuation if execution continues. 2026 Revenue Guidance & Platform Expansion (MSN)
• Neutral Sentiment: Company announced a leadership transition framed as supporting the next phase of growth — this is management-level news to monitor for execution risk but not an immediate negative. Leadership Transition (Yahoo)
• Neutral Sentiment: Analyst note roundup summarizes 11 analysts’ views — useful context on street sentiment and target dispersion but adds no single new catalyst. Analyst Roundup: 11 Analysts (Benzinga)
• Negative Sentiment: Market reaction: shares are trading lower today despite the earnings beat, guidance and several price‑target raises — suggests some profit‑taking or skepticism about margins/near‑term profitability. Market Reaction

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.